Anti-PD-L1 Antibody, Mouse Monoclonal

RRID Number: AB_2860075
1/3
Price:
Size:
Number:

Anti-PD-L1 Antibody, Mouse Monoclonal General Information

Product name
Anti-PD-L1 Antibody, Mouse Monoclonal
Validated applications
IHC-P
Species reactivity
Reacts with: Human
Specificity
Human PD-L1
Immunogen
Recombinant Human PD-L1 / B7-H1 / CD274 protein (Catalog#10084-H08H)
Preparation
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human PD-L1 / B7-H1 / CD274 (rh PD-L1 / B7-H1 / CD274; Catalog#10084-H08H; NP_054862.1; Met1-Thr239). The IgG fraction of the cell culture supernatant was purified by Protein A affinity.
Source
Monoclonal Mouse IgG1 Clone #B55
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-PD-L1 Antibody, Mouse Monoclonal Validated Applications

Application Dilution
IHC-P 1:20-1:80
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-PD-L1 Antibody, Mouse Monoclonal Images

Immunochemical staining of human B7-H1 in human lung cancer with mouse monoclonal antibody (1:30, formalin-fixed paraffin embedded sections).
Immunochemical staining of human B7-H1 in human malignant melanoma with mouse monoclonal antibody (1:30, formalin-fixed paraffin embedded sections).
Immunochemical staining of human B7-H1 in human placenta with mouse monoclonal antibody (1:30, formalin-fixed paraffin embedded sections).

Anti-PD-L1 Antibody, Mouse Monoclonal: Synonyms

Anti-B7-H Antibody; Anti-B7-H1 Antibody; Anti-B7H1 Antibody; Anti-PD-L1 Antibody; Anti-PDCD1L1 Antibody; Anti-PDCD1LG1 Antibody; Anti-PDL1 Antibody

PD-L1 Background Information

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
Full Name
CD274 molecule
Research Areas
References
  • Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
  • Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
  • Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
  • Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
  • Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
  • Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens
    Author
    Wedekind, MF;Haworth, KB;Arnold, M;Stanek, JR;Lee, D;Cripe, TP;
    Year
    2018
    Journal
    Pediatr Blood Cancer
    Application
    IHC

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.